Background Image

ASBM Advisory Board Member Quoted in Inside Health Policy Article

On March 14, ASBM Advisory Board Member, Dr. Harry Gewanter was quoted in the Inside Health Policy Article “North Dakota Projects Lost Savings With Biosimilar Bill; Cost Debate Heats Up.” The article says:

“Harry Gewanter, a pediatric rheumatologist and Alliance for Safe Biologic Medicines board member, rebutted arguments from the sponsor of the Virginia bill, which has since been signed into law, that it would lower drug costs, saying it was ‘pure speculation.’ He further said cost concerns are less important than safety monitoring of these riskier drugs.

“Chronic illness care requires close and ongoing communication between all members of a patient’s health care team. As a physician and a parent, I believe this communication and the resultant patient safety is far more important than any theoretical monetary savings Sen. (Steve) Newman (R) touts.”

Read the full article here.

Background Image

ASBM Advisory Board Member Quoted in Inside Health Policy Article

On March 14, ASBM Advisory Board Member, Dr. Harry Gewanter was quoted in the Inside Health Policy Article “North Dakota Projects Lost Savings With Biosimilar Bill; Cost Debate Heats Up.” The article says:

“Harry Gewanter, a pediatric rheumatologist and Alliance for Safe Biologic Medicines board member, rebutted arguments from the sponsor of the Virginia bill, which has since been signed into law, that it would lower drug costs, saying it was ‘pure speculation.’ He further said cost concerns are less important than safety monitoring of these riskier drugs.

“Chronic illness care requires close and ongoing communication between all members of a patient’s health care team. As a physician and a parent, I believe this communication and the resultant patient safety is far more important than any theoretical monetary savings Sen. (Steve) Newman (R) touts.”

Read the full article here.

logo logo logo